Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (300255.SZ)
CNY 20.19
(-0.39%)
CNY 20.19
(-0.39%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.54 Billion CNY | -12.26% |
| 2022 | 902.09 Million CNY | -35.08% |
| 2021 | 1.38 Billion CNY | 11.9% |
| 2020 | 1.24 Billion CNY | 3.7% |
| 2019 | 1.19 Billion CNY | 34.17% |
| 2018 | 892.42 Million CNY | 34.1% |
| 2017 | 665.48 Million CNY | 33.81% |
| 2016 | 497.32 Million CNY | 21.92% |
| 2015 | 407.91 Million CNY | 34.02% |
| 2014 | 304.36 Million CNY | 22.49% |
| 2013 | 248.48 Million CNY | 44.04% |
| 2012 | 172.51 Million CNY | 245.22% |
| 2011 | 49.97 Million CNY | 12.27% |
| 2010 | 44.51 Million CNY | 80.16% |
| 2009 | 24.7 Million CNY | 61.52% |
| 2008 | 15.29 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 32.86 Million CNY | -53.62% |
| 2024 Q3 | 46.17 Million CNY | 97.32% |
| 2024 Q1 | 70.86 Million CNY | -68.82% |
| 2023 Q1 | 169.53 Million CNY | -1.78% |
| 2023 Q2 | 209.69 Million CNY | 23.69% |
| 2023 FY | 791.53 Million CNY | -12.26% |
| 2023 Q3 | 185.01 Million CNY | -11.77% |
| 2023 Q4 | 227.27 Million CNY | 22.84% |
| 2022 Q3 | 259.31 Million CNY | 8.56% |
| 2022 FY | 902.09 Million CNY | -35.08% |
| 2022 Q4 | 172.6 Million CNY | -33.44% |
| 2022 Q2 | 238.85 Million CNY | 3.26% |
| 2022 Q1 | 231.32 Million CNY | -36.35% |
| 2021 Q1 | 339.14 Million CNY | -5.27% |
| 2021 FY | 1.38 Billion CNY | 11.9% |
| 2021 Q3 | 369.21 Million CNY | 16.24% |
| 2021 Q2 | 317.63 Million CNY | -6.34% |
| 2021 Q4 | 363.45 Million CNY | -1.56% |
| 2020 FY | 1.24 Billion CNY | 3.7% |
| 2020 Q1 | 231.13 Million CNY | -40.28% |
| 2020 Q4 | 358.02 Million CNY | 2.93% |
| 2020 Q3 | 347.85 Million CNY | 14.19% |
| 2020 Q2 | 304.61 Million CNY | 31.79% |
| 2019 Q2 | 232.17 Million CNY | -7.36% |
| 2019 FY | 1.19 Billion CNY | 34.17% |
| 2019 Q1 | 250.63 Million CNY | -13.34% |
| 2019 Q3 | 327.48 Million CNY | 41.05% |
| 2019 Q4 | 387.03 Million CNY | 18.18% |
| 2018 Q1 | 167.87 Million CNY | -27.51% |
| 2018 Q2 | 189.58 Million CNY | 12.94% |
| 2018 Q4 | 289.22 Million CNY | 17.7% |
| 2018 Q3 | 245.73 Million CNY | 29.61% |
| 2018 FY | 892.42 Million CNY | 34.1% |
| 2017 Q3 | 175.06 Million CNY | 19.57% |
| 2017 FY | 665.48 Million CNY | 33.81% |
| 2017 Q1 | 112.4 Million CNY | 8.42% |
| 2017 Q4 | 231.59 Million CNY | 32.29% |
| 2017 Q2 | 146.41 Million CNY | 30.25% |
| 2016 Q4 | 103.67 Million CNY | -34.62% |
| 2016 FY | 497.32 Million CNY | 21.92% |
| 2016 Q1 | 107.3 Million CNY | -3.27% |
| 2016 Q3 | 158.57 Million CNY | 24.11% |
| 2016 Q2 | 127.77 Million CNY | 19.08% |
| 2015 Q1 | 92.42 Million CNY | 44.92% |
| 2015 Q4 | 110.92 Million CNY | -3.85% |
| 2015 Q3 | 115.37 Million CNY | 29.34% |
| 2015 Q2 | 89.19 Million CNY | -3.49% |
| 2015 FY | 407.91 Million CNY | 34.02% |
| 2014 Q4 | 63.77 Million CNY | -35.51% |
| 2014 FY | 304.36 Million CNY | 22.49% |
| 2014 Q1 | 62 Million CNY | -0.63% |
| 2014 Q2 | 79.7 Million CNY | 28.54% |
| 2014 Q3 | 98.88 Million CNY | 24.06% |
| 2013 Q4 | 62.39 Million CNY | -8.87% |
| 2013 FY | 248.48 Million CNY | 44.04% |
| 2013 Q1 | 48.52 Million CNY | 3.61% |
| 2013 Q2 | 69.09 Million CNY | 42.4% |
| 2013 Q3 | 68.47 Million CNY | -0.9% |
| 2012 Q3 | 56.1 Million CNY | 31.21% |
| 2012 Q2 | 42.76 Million CNY | 59.44% |
| 2012 Q1 | 26.81 Million CNY | 112.28% |
| 2012 FY | 172.51 Million CNY | 245.22% |
| 2012 Q4 | 46.83 Million CNY | -16.53% |
| 2011 Q3 | 15.18 Million CNY | 22.82% |
| 2011 Q4 | 12.63 Million CNY | -16.78% |
| 2011 FY | 49.97 Million CNY | 12.27% |
| 2011 Q2 | 12.36 Million CNY | 26.17% |
| 2011 Q1 | 9.79 Million CNY | -25.98% |
| 2010 Q3 | 9.7 Million CNY | 0.0% |
| 2010 FY | 44.51 Million CNY | 80.16% |
| 2010 Q4 | 13.23 Million CNY | 36.39% |
| 2009 FY | 24.7 Million CNY | 61.52% |
| 2008 FY | 15.29 Million CNY | 0.0% |